“…Unlike BMAA [41,42], cycasin and MAM readily cross the blood-brain barrier with ϳ5% of either administered agent detected in brain tissue (GK, unpublished data; [43]) ( Table 1). Depending on the route (i.e., oral or topical) of cycad exposure, cycasin gains access to brain tissue via a high-capacity brain endothelial [44,45] or intestinal [46] Na ϩ -dependent glucose transporter (SGLT). Cycasin shows a 100 times greater affinity for the brain endothelial SGLT, suggesting that the genotoxin is rapidly transported by the brain SGLT before it liberates MAM, presumably by enzymatic action of cytosolic (neutral) β-glucosidase.…”